CD70 and nodal marginal zone B-cell lymphoma: No additional case with a CD70 mutation was found in the validation cohort; however, 61.1% (22/36) of NMZL cases showed loss or attenuated expression of CD70 by immunohistochemistry (IHC) (Figure 2C), indicating alteration of the immune-stimulatory molecule CD70 in NMZLs.